FDA Greenlights High-Dose Wegovy for Amplified Weight Loss Outcomes
The U.S. Food and Drug Administration has given the green light to a higher-dose version of Novo Nordisk’s blockbuster obesity drug, Wegovy, on March 19, 2026. This marks a pivotal advancement in the weight loss medication market as the Danish pharmaceutical giant aims to compete more effectively with its rival, Eli Lilly.
The FDA has given its approval for a 7.2-milligram dose of semaglutide, the active ingredient in Wegovy, tripling the previously highest approved dose of 2.4 milligrams. The new formulation, dubbed Wegovy HD, will hit the shelves of U.S. pharmacies in April 2026.
Clinical trial results have demonstrated that patients consuming the higher dose shed approximately 20.7% of their body weight after 72 weeks, or about 47 pounds on average, compared to a 16% weight loss with the lower dose. In patients grappling with both obesity and type 2 diabetes, the higher dosage showcased an average weight loss of 14.1%.
The approval was fast-tracked through the FDA’s National Priority Voucher program, with approval granted a mere 54 days post the acceptance of the request. This is the fourth product to be approved under this accelerated program designed to hasten treatments addressing critical national health priorities.
However, the higher dose is not without its increased side effects. Over 70% of participants consuming the higher dose reported gastrointestinal issues such as nausea, vomiting, or constipation, compared to 60% on the lower dose. Additionally, about 23% experienced altered skin sensations like burning or tingling, compared to a mere 6% on the lower dose.
Dr. Jody Dushay, an endocrinologist at Harvard Medical School, opined that the approval “may be especially helpful for people” who can tolerate the lower dose but “have had suboptimal weight loss.”
Source: CNBC